Status:
ACTIVE_NOT_RECRUITING
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD
Lead Sponsor:
Erasmus Medical Center
Conditions:
Pulmonary Fibrosis
Eligibility:
All Genders
Brief Summary
The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for dia...
Detailed Description
Patients will be included in the study after signing written informed consent. eNose measurements will take place before or after a routine outpatient clinic visit at the same location as the regular ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of fibrotic ILD, as discussed in a multidisciplinary team meeting (50% incident patients and 50% prevalent patients). Patients are classified as 'incident' if they received a diagnosed in a multidisciplinary team meeting within the past six months. Patients will be required to have fibrosis on a HRCT scan \<1 year before enrollment in the study defined as reticular abnormality with traction bronchiectasis, with or without honeycombing, as determined by a radiologist. No minimum extent of fibrosis will be required.
Exclusion
- Alcohol consumption ≤ 12 hours before the measurement
- Physically not able to perform eNose measurement
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04680832
Start Date
November 1 2020
End Date
December 31 2026
Last Update
June 18 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, NSW 2050
2
University Lyon 1, Louis Pradel hospital, Lyon. FranceService de pneumologie, hôpital Louis Pradel
Lyon, France
3
Thoraxklinik Heidelberg
Heidelberg, Germany, 69126
4
Erasmus MC
Rotterdam, Netherlands, 3000 CA